Tenvie Therapeutics, a Denali spinout, raises $200M as neuro
Jan 8, 2025 · The biotech, called Tenvie Therapeutics, launched Wednesday with $200 million from ARCH Venture Partners — one of Denali’s early investors — as well as F-Prime Capital, Mubadala Capital, and...
Tenvie takes off with $200M, assets and exec from Denali
Jan 8, 2025 · Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing several programs—and an executive—from Denali Therapeutics.
Tenvie Therapeutics Launches with $200 Million to Deliver …
Jan 8, 2025 · Tenvie is developing a portfolio of wholly owned, highly brain-penetrant and peripherally restricted small molecules that address three key drivers of disease: resolving inflammation, rescuing metabolic dysfunction, and restoring lysosomal function.
Tenvie Debuts With Denali Assets, $200M for Neurological
Jan 8, 2025 · Tenvie Therapeutics has launched with $200 million and a clutch of assets from Denali Therapeutics to go after neurological diseases with small molecules. Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of brain-penetrant small molecules to address inflammation, metabolic ...
Tenvie Therapeutics Launches with $200 Million to Deliver …
Jan 8, 2025 · Tenvie is developing a portfolio of wholly owned, highly brain-penetrant and peripherally restricted small molecules that address three key drivers of disease: resolving inflammation, rescuing ...
Tenvie Therapeutics Launches with $200M for Breakthrough …
Jan 9, 2025 · Tenvie Therapeutics launched with $200 million in funding to develop small molecule treatments for neurological diseases. The company acquired assets from Denali Therapeutics and assembled a leadership team with expertise in …
Tenvie Therapeutics Launches with $200 Million to Deliver …
Jan 8, 2025 · Advancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseases. Led by expert R&D leadership team with proven ability to develop therapies...
Tenvie Therapeutics Launches with $200 Million to Deliver
Jan 9, 2025 · Tenvie is advancing a pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseases. Its portfolio of wholly owned, highly brain-penetrant, and precision-designed peripherally restricted small molecules address three key drivers of disease: resolving inflammation, rescuing metabolic dysfunction, and ...
Tenvie launches with $200m to combat age-related diseases
Jan 10, 2025 · Backed with a whopping $200 million in funding, US biotech Tenvie Therapeutics has launched to advance new treatments for neurological, cardiometabolic and ophthalmic diseases. Based in South San Francisco, the company has acquired small-molecule programs and its discovery team from Denali Therapeutics as it seeks to develop therapies that ...
Tenvie raises $200M for brain drug R&D; Sana spikes on single …
Jan 8, 2025 · A new San Francisco-area startup, Tenvie Therapeutics, launched on Wednesday with $200 million in funding. Tenvie is supported by Arch Venture Partners, F-Prime Capital and Mubadala Capital, and is built around drug assets from …